Literature DB >> 10689270

beta2-adrenergic receptor polymorphisms at amino acid 16 differentially influence agonist-stimulated blood pressure and peripheral blood flow in normal individuals.

B D Hoit1, D P Suresh, L Craft, R A Walsh, S B Liggett.   

Abstract

BACKGROUND: The Gly16 beta(2)-adrenergic receptor (beta(2)AR) polymorphism is a common variant of the beta(2)AR that displays depressed function caused by enhanced receptor downregulation in vitro compared with the Arg16 receptor. METHODS AND
RESULTS: We studied 20 healthy, normotensive, nonsmoking white individuals who were homozygous for either the Arg16 (n = 10) or the Gly16 (n = 10) genotype. Plethysmographic lower-limb blood flow, blood pressure, and 2-dimensional echocardiograms were recorded at baseline and after 15-minute incremental infusions of terbutaline (100 to 300 ng/kg per minute). Baseline heart rates, blood pressures, and flows were similar in both groups, but at the maximum dose of terbutaline, limb blood flow was less (P <.05), calculated vascular resistance was greater (P <.05), and systolic and diastolic blood pressures were greater in patients with Gly16 than in those with Arg16 (both P <.05). In contrast, terbutaline-stimulated heart rates were not different. In a separate group of 20 homozygous individuals (12 Arg16, 8 Gly16), there were no differences in 2-dimensional echocardiographically determined ventricular function.
CONCLUSIONS: We conclude that the Gly16 beta(2)AR polymorphism imparts attenuated vasodilatory responses to catecholamines in normal human beings and is an important genetic component in the regulation of peripheral blood flow and systemic arterial pressure.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10689270     DOI: 10.1016/s0002-8703(00)90099-1

Source DB:  PubMed          Journal:  Am Heart J        ISSN: 0002-8703            Impact factor:   4.749


  27 in total

Review 1.  Genetic determinants of vascular reactivity.

Authors:  Daniel Henrion; Joelle Benessiano; Marc Iglarz; Ivan Philip; Bernard I Levy
Journal:  Curr Hypertens Rep       Date:  2002-02       Impact factor: 5.369

Review 2.  Genetic polymorphisms of adrenergic receptors.

Authors:  E M Garland; I Biaggioni
Journal:  Clin Auton Res       Date:  2001-04       Impact factor: 4.435

Review 3.  Beta-adrenoceptor polymorphisms.

Authors:  K Leineweber; R Büscher; H Bruck; O-E Brodde
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2003-11-28       Impact factor: 3.000

4.  Functional adrenergic receptor polymorphisms and idiopathic orthostatic intolerance.

Authors:  R Winker; A Barth; E Valic; R Maier; W Osterode; A Pilger; H W Rüdiger
Journal:  Int Arch Occup Environ Health       Date:  2005-02-18       Impact factor: 3.015

Review 5.  The genomic architecture of sporadic heart failure.

Authors:  Gerald W Dorn
Journal:  Circ Res       Date:  2011-05-13       Impact factor: 17.367

Review 6.  {beta}-Adrenoceptor gene variation and intermediate physiological traits: prediction of distant phenotype.

Authors:  John H Eisenach; Erica D Wittwer
Journal:  Exp Physiol       Date:  2010-04-09       Impact factor: 2.969

7.  No positive association between adrenergic receptor variants of alpha2cDel322-325, beta1Ser49, beta1Arg389 and the risk for heart failure in the Japanese population.

Authors:  Shinpei Nonen; Hiroshi Okamoto; Masatoshi Akino; Yutaka Matsui; Yasushi Fujio; Minoru Yoshiyama; Yasuhiko Takemoto; Junichi Yoshikawa; Junichi Azuma; Akira Kitabatake
Journal:  Br J Clin Pharmacol       Date:  2005-10       Impact factor: 4.335

8.  β2 adrenergic interaction and cardiac autonomic function: effects of aerobic training in overweight/obese individuals.

Authors:  Jhennyfer Aline Lima Rodrigues; Gustavo Duarte Ferrari; Átila Alexandre Trapé; Vitor Nolasco de Moraes; Thiago Correa Porto Gonçalves; Simone Sakagute Tavares; Arnt Erik Tjønna; Hugo Celso Dutra de Souza; Carlos Roberto Bueno Júnior
Journal:  Eur J Appl Physiol       Date:  2020-01-08       Impact factor: 3.078

9.  Roles of beta2- and beta3-adrenoceptor polymorphisms in hypertension and metabolic syndrome.

Authors:  Kazuko Masuo
Journal:  Int J Hypertens       Date:  2010-10-21       Impact factor: 2.420

Review 10.  Chronic heart failure: beta-blockers and pharmacogenetics.

Authors:  Junichi Azuma; Shinpei Nonen
Journal:  Eur J Clin Pharmacol       Date:  2008-10-07       Impact factor: 2.953

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.